Dynavax to Present at HC Wainwright’s 4th Annual Hepatitis B Virus Virtual Conference

Emeryville, California, October 19, 2023 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it will be present at the HC Wainwright 4th Annual Hepatitis Virus Annual Virtual Conference Wednesday, October 25 exist 1:00 p.m. Eastern Time.

The presentation will be conducted via a live webcast and can be accessed through the Events and Presentations page of the Investors section of the Company’s website at https://investors.dynavax.com/events-presentations.

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The company has two commercial products, HEPLISAV-B^® Vaccine (Hepatitis B vaccine (recombinant), adjuvant), already available in the United States, the European Union and Great Britain For the prevention of infection caused by all known hepatitis B virus subtypes in adults 18 years of age and older, plus CpG 1018^®

Adjuvants currently used in multiple adjuvants for COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant into clinical programs for adjuvant vaccines against herpes zoster and Tdap as a first-line vaccine adjuvant, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and general influenza .For more information about our marketing products and development pipeline, please visit www.dynavax.com and follow Dynavax on LinkedIn and Twitter.

For investors/media:
Paul Cox
(email protected)
510-665-0499

Nicole Arndt
(email protected)
510-665-7264

SOURCE Dynavax Technologies